---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: EMERGE"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: EMERGE. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 44 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence/emerge"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: EMERGE

<a id="heading-3.1.1"></a>

## 3.1.1 EMERGE

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.1-2"></a>

#### Trial aim stated in the company announcement of initiation

> “EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2026-06-29”
> “Primary Completion (Estimated) 2028-12”
> “Study Completion (Estimated) 2031-09”
> “First Posted 2026-06-15”
> “Last Update Posted 2026-10-30”
> “Recruiting”
> “No Results Posted”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 12 locations”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.2-3"></a>

#### Study locations by country in the ClinicalTrials.gov record

| Country | Locations listed in the record |
| --- | --- |
| United States | “Pasadena, California, United States, 91106”; “Boca Raton, Florida, United States, 33432”; “Fayetteville, North Carolina, United States, 28304”; “Houston, Texas, United States, 77009” |
| Georgia | “Kutaisi, Georgia”; “Tbilisi, Georgia” |
| Ukraine | “Dnipro, Ukraine”; “Vinnytsia, Ukraine” |

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.2-4"></a>

#### Initiation announced by the company in June 2026

> “NEW YORK and WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced initiation of the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis (gMG).”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

<a id="topic-3.1.1.2-5"></a>

#### Expected timing of top-line results in the third-quarter 2026 filing

> “In June 2026, we announced the initiation of the Phase 3 registrational EMERGE trial of claseprubart in gMG. We expect to report top-line results from this trial in the second half of 2028.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="topic-3.1.1.2-6"></a>

#### Expected timing of top-line results in the third-quarter 2026 results announcement

> “Phase 3 EMERGE trial on track with top-line results expected in 2H’28: A Phase 3 registrational trial of claseprubart evaluating 300mg/2mL S.C. Q2W and 300mg/2mL S.C. Q4W in gMG patients was initiated in June, with top-line results expected in 2H’28.”

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

<a id="topic-3.1.1.2-7"></a>

#### Planned update of top-line guidance in the November 2026 corporate deck

> “Claseprubart Updated Ph. 3 EMERGE top-line guidance (YE’27)”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.2-8"></a>

#### Member states and estimated dates in the EU trial record

> “Locations Austria, Bulgaria, Czechia, Denmark, France, Germany, Italy, Latvia, Portugal, Spain, Poland”
> “Estimated recruitment start date in EU/EEA: 10/01/2027”
> “Estimated end of trial date in EU/EEA: 26/07/2031”
> “Estimated global end date of the trial: 24/01/2032”

Source: [EU Clinical Trials Information System 2026-525298-38-00](https://euclinicaltrials.eu/ctis-public/view/2026-525298-38-00)

<a id="topic-3.1.1.2-9"></a>

#### Status and decision date by member state in the EU trial record

> “Denmark Authorised, recruitment pending 28/09/2026”
> “France Authorised, recruitment pending 28/09/2026”
> “Latvia Authorised, recruitment pending 28/09/2026”
> “Portugal Authorised, recruitment pending 29/09/2026”
> “Czech Republic Authorised, recruitment pending 29/09/2026”
> “Bulgaria Authorised, recruitment pending 29/09/2026”
> “Germany Authorised, recruitment pending 30/09/2026”
> “Poland Authorised, recruitment pending 01/10/2026”
> “Italy Authorised, recruitment pending 01/10/2026”
> “Spain Authorised, recruitment pending 02/10/2026”
> “Austria Authorised, recruitment pending 05/10/2026”

Source: [EU Clinical Trials Information System 2026-525298-38-00](https://euclinicaltrials.eu/ctis-public/view/2026-525298-38-00)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Official title in the ClinicalTrials.gov record

> “A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients With Generalized Myasthenia Gravis (EMERGE)”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.3-2"></a>

#### Study periods in the ClinicalTrials.gov detailed description

> “The study includes the following periods: Screening (up to 12 weeks) Randomized, blinded, controlled treatment (RCT) period (17 weeks) Extended treatment period (ETP) (104 weeks) (optional) for eligible participants [includes blinded extension period (BEP) and open-label extension (OLE) period] Safety Follow-Up period (40 weeks)”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.3-3"></a>

#### Allocation, model, and masking in the ClinicalTrials.gov record

> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Quadruple”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.3-4"></a>

#### Design described by the company at initiation

> “EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial in approximately 195 participants with generalized Myasthenia Gravis who are acetylcholine receptor antibody positive (AChR+).”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

<a id="topic-3.1.1.3-5"></a>

#### Design summary in the November 2026 corporate deck

> “EMERGE is a global Ph. 3 trial evaluating Q4W and Q2W S.C. claseprubart in AChR+ gMG; top-line data 2H’28”
> “Design: Male and female subjects randomized to receive either claseprubart or placebo for 17 weeks”
> “No ANA screening exclusion criteria or routine ANA testing during RCT or OLE, inclusion criteria of MG-ADL of ≥6 and QMG of ≥10, and 17-week S.C. treatment period per alignment with FDA”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.3-6"></a>

#### End-of-phase 2 meeting with FDA before the phase 3 trial

> “Following the successful completion of our end-of-Phase 2 meeting with the FDA in the first quarter of 2026, a Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W S.C. and 300mg/2mL Q4W S.C. in gMG patients is on track to initiate in mid-2026, with top-line results expected in 2H’28.”

Source: [Dianthus Therapeutics (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-ex99_1.htm)

> “In September 2025, we reported positive top-line results from the Phase 2 MaGic trial of claseprubart for patients with gMG and subsequently held an end-of-Phase 2 meeting with the FDA in the first quarter of 2026.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Key inclusion criteria in the ClinicalTrials.gov record

> “Weight range between 40-130 kg at Screening”
> “Acetylcholine receptor antibody (AChR Ab) positive”
> “i. History of abnormal neuromuscular transmission test; ii. History of positive anticholinesterase test; iii. Clinical response to acetylcholinesterase inhibitors.”
> “Myasthenia Gravis Foundation of America (MGFA) Class II-IVa”
> “MG-ADL scale score of 6 or more”
> “QMG scale score of 10 or more”
> “Documented vaccinations against encapsulated bacteria in accordance with local requirements and based on vaccine availability”
> “Ages Eligible for Study 18 Years to 80 Years”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.4-2"></a>

#### Key exclusion criteria in the ClinicalTrials.gov record

> “Known complement deficiency”
> “Prior history (at any time) of N. meningitidis infection”
> “Previous treatment with claseprubart (DNTH103) or participation in a clinical trial with claseprubart.”
> “Any thymic surgery/biopsy within 1 year of Screening”
> “Any known or untreated thymoma.”
> “Rituximab or other B-cell targeting therapies (ie, inebilizumab) within 6 months (180 days) prior to randomization (Day 1)”
> “Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) within 4 weeks (28 days) prior to randomization (Day 1)”
> “Diagnosis of systemic lupus erythematosus (SLE) or family history (defined as a parent, sibling, or child) of SLE”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.4-3"></a>

#### Inclusion criteria in the November 2026 corporate deck

> “Inclusion: ≥18 years old with AChR antibody + gMG, MG-ADL of ≥6 and QMG of ≥10”
> “No ANA screening exclusion criteria or routine ANA testing during the RCT or OLE”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.4-4"></a>

#### Company rationale for the QMG screening criterion

> “Adding QMG screening criteria in Ph. 3, similar to zilucoplan Ph. 3”
> “may better control for placebo response”
> “Ph. 2 study did not include QMG inclusion criteria, similar to ravulizumab Ph. 3; post-hoc analysis of MaGic data demonstrates potentially best-in-class MG-ADL improvement in patients with QMG ≥10”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.4-5"></a>

#### Removal of antinuclear antibody screening after FDA written feedback

> “Removal of anti-nuclear antibodies ("ANAs") as a screening criteria, a common reason for screen failure across all three claseprubart programs”
> “In March 2026, the Company received written feedback from FDA agreeing to all three of these proposals for all ongoing and planned future claseprubart trials.”

Source: [Dianthus Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000010/dnth-20260326.htm)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Arms and interventions in the ClinicalTrials.gov record

| Arm | Intervention described in the record |
| --- | --- |
| Claseprubart every 2 weeks | “IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart Q2W starting at Week 1 (Day 8).” |
| Claseprubart every 4 weeks | “IV loading dose of claseprubart on Day 1 followed by SC injections of claseprubart or Placebo Q2W starting at Week 1 (Day 8), with doses alternating between claseprubart and placebo.” |
| Placebo | “Intravenous (IV) infusion of Placebo on Day 1 followed by subcutaneous (SC) injections of Placebo every 2 weeks (Q2W) starting at Week 1 (Day 8).” |
| Subcutaneous product | “Prefilled syringe containing claseprubart for SC administration” |

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.5-2"></a>

#### Dose and route stated by the company

> “Following an initial loading dose, claseprubart 300mg/2mL will be administered every two or four weeks (Q2W or Q4W) via subcutaneous (S.C.) injection.”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

> “Dosing: I.V. Loading Dose followed by 300mg/2mL S.C. Q2W or Q4W starting Day 7”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.5-3"></a>

#### Rationale for the every-4-weeks regimen from the phase 2 open-label extension

> “OLE data support addition of 300mg/2mL Q4W in Ph. 3”
> “PK of ~65 μg/mL at week 4 after only two 600mg/4mL doses is substantially lower than steady state seen with 300mg/2mL dosing of ~100-120 μg/mL”
> “Robust reductions in MG-ADL and QMG are achieved by week 4, after just two 600mg/4mL doses and remain stable in subsequent weeks”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “Data from the OLE demonstrate that after two doses of claseprubart 600mg Q2W, participants experienced robust reductions in MG-ADL and QMG at PK levels far below the steady state of the 300mg Q2W dose, supporting the potential for dosing of 300mg claseprubart every four weeks”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using MG-ADL as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary outcome measure in the ClinicalTrials.gov record

> “Change from Baseline to Week 17 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score”
> “Baseline (Day 1) to Week 17”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.6.1-2"></a>

##### Secondary outcome measures in the ClinicalTrials.gov record

> “Change from Baseline to Week 17 in Quantitative Myasthenia Gravis (QMG) Scale Score”
> “Change from Baseline to Week 17 in Myasthenia Gravis Composite (MGC) Scale Score”
> “Proportion of Participants with Greater Than or Equal to (≥) a 5-point Reduction in MG-ADL Scale Score at Week 17 Compared to Baseline”
> “Proportion of Participants Who Reach Minimal Symptom Expression (MSE), Defined as MG-ADL 0 or 1 at Week 17, Without Use of Rescue Therapy”
> “Proportion of Participants with a ≥ 5-point Reduction in QMG Scale Score at Week 17 Compared to Baseline”
> “Number of participants with TEAEs and treatment-emergent SAEs will be reported.”
> “Serum Concentrations of Claseprubart”
> “Change from Baseline in Complement Total Blood Test (CH50) in Serum ex vivo”
> “Incidence of Antidrug Antibody (ADAs) Against Claseprubart in the RCT Period, BEP, OLE, and Safety Follow-Up”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.6.1-3"></a>

##### Primary and secondary endpoints stated by the company

> “The primary endpoint of this trial is the change from baseline in the MG-ADL in the treatment arms versus the placebo arm. A similar evaluation is used for secondary efficacy endpoints, such as the QMG scale, MSE, MGC score and the MG-QoL-15r.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

> “Primary: MG-ADL change from baseline”
> “Secondary / Exploratory: Efficacy (QMG, MSE, MGC, MG-QoL-15r)”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.6.1-4"></a>

##### MG-ADL scale described in the ClinicalTrials.gov record

> “The MG-ADL score is an 8-item patient reported outcome (PRO) instrument. The MG-ADL targets symptoms of disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of the MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability.”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.6.1-5"></a>

##### Validity, reliability, and use of the MG-ADL as a primary endpoint

> “Studies indicated that the MG‐ADL is a reliable and valid measure that has been used as an outcome in clinical trials and observational studies to measure MG symptoms and response to treatment. While most often used as a secondary endpoint in clinical trials, its use as a primary endpoint has increased in recent years.”
> “Since trial completion and publication of results for the phase 3 trial of eculizumab, the use of the MG‐ADL as a primary endpoint in trials has become widespread. Of trials beginning in 2018 or later, 46.7% (n = 7) have used the MG‐ADL as a primary outcome compared to 10.0% (n = 2) of trials prior to 2018”
> “The MG‐ADL is easy to administer, requires no additional training, is quick to complete (<10 min), and can be used in routine clinical”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

<a id="topic-3.1.1.6.1-6"></a>

##### Minimal clinically important difference: 2-point improvement in the validation study

> “Correlation of the delta MG-ADL score and physician impression of change between the visits was strong (r = 0.70, P < 0.0001). A 2-point improvement in the MG-ADL best predicted clinical improvement.”
> “The MG-ADL correlates strongly with newer, validated MG outcome measures. A 2-point improvement in the MG-ADL indicates clinical improvement.”

Source: [Muppidi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22006686/)

<a id="topic-3.1.1.6.1-7"></a>

##### Minimal clinically important difference: sensitivity and specificity of each threshold

> “In this study, results from sensitivity and specificity analyses indicated that a 1‐point change in MG‐ADL was highly sensitive (96%) but did not have good specificity (71%), and a 3‐point change had good specificity (90%) but was not very sensitive (62%). A 2‐point change seemed to provide the best balance between sensitivity (77%) and specificity (82%); thus, this analysis revealed that a 2‐point improvement in MG‐ADL score best indicated clinical improvement.”
> “Of these 13 studies, 53.8% (n = 7) used a 2‐point improvement only, 30.8% (n = 4) used a 3‐point improvement only”

Source: [Muppidi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9302997/)

<a id="topic-3.1.1.6.1-8"></a>

##### Primary endpoint in the pivotal trial of eculizumab

> “The primary efficacy endpoint for Study ECU-MG-301 was a comparison of the change from baseline between treatment groups in the Myasthenia Gravis-Specific Activities of Daily Living scale (MG-ADL) total score at Week 26.”

Source: [Soliris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125166s454lbl.pdf)

<a id="topic-3.1.1.6.1-9"></a>

##### Primary endpoint in the pivotal trial of ravulizumab

> “The primary efficacy endpoint was a comparison of the change from baseline between treatment groups in the MG-ADL total score at Week 26.”

Source: [Ultomiris prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761108s046lbl.pdf)

<a id="topic-3.1.1.6.1-10"></a>

##### Primary endpoint in the pivotal trial of zilucoplan

> “The primary efficacy endpoint was a comparison of the change from baseline between treatment groups in the Myasthenia Gravis-Specific Activities of Daily Living scale (MG- ADL) total score after twelve weeks of treatment.”

Source: [Zilbrysq prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/216834s015lbl.pdf)

<a id="topic-3.1.1.6.1-11"></a>

##### Primary endpoints in the pivotal trials of efgartigimod alfa

> “In this study, an MG- ADL responder was defined as a patient with a 2-point or greater reduction in the total MG-ADL score compared to the treatment cycle baseline for at least 4 consecutive weeks, with the first reduction occurring no later than 1 week after the last infusion of the cycle.”
> “The primary efficacy endpoint was the comparison of the percentage of MG-ADL responders during the first treatment cycle between treatment groups in the anti-AChR antibody positive population.”
> “The primary efficacy endpoint was the comparison of the mean change from baseline at Week 4 between treatment groups in the MG-ADL total score.”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-3.1.1.6.1-12"></a>

##### Primary endpoint in the pivotal trial of rozanolixizumab

> “The primary efficacy endpoint was the comparison of the change from baseline between treatment groups in the MG-ADL total score at day 43.”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-3.1.1.6.1-13"></a>

##### Primary endpoint in the pivotal trial of nipocalimab

> “The primary efficacy endpoint was the comparison of the mean change from baseline to Weeks 22, 23, and 24 between treatment groups in the MG-ADL total score.”

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-3.1.1.6.1-14"></a>

##### Company target for the MG-ADL treatment difference

> “Targeting >2-point MG-ADL improvement vs. placebo”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-3.1.1.6.1-15"></a>

##### Secondary endpoints: QMG and MGC scales described in the ClinicalTrials.gov record

> “The QMG is a clinician-reported assessment to evaluate muscle strength. The QMG consists of 13 items that measure endurance or fatiguability, with each item having a possible score that ranges from 0 - 3. The total possible QMG scores range from 0 - 39, with a higher score indicating greater disease burden.”
> “The MGC is a validated assessment tool for measuring clinical status of participants with MG. The range of total MGC score is 0 to 50, with higher scores indicating more severe disease. A clinically meaningful improvement is reflected by a 3-point improvement in MGC score.”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 195”

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510)

<a id="topic-3.1.1.7.1-2"></a>

##### Planned enrollment stated by the company

> “The EMERGE trial is a global, randomized, multicenter, placebo-controlled Phase 3 trial of claseprubart in approximately 195 AChR+ participants with gMG.”

Source: [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm)

<a id="topic-3.1.1.7.1-3"></a>

##### Planned participants per arm in the November 2026 corporate deck

| Arm | Planned participants |
| --- | --- |
| Claseprubart every 2 weeks | “300mg/2mL S.C. Q2W (N=65)” |
| Claseprubart every 4 weeks | “Claseprubart 300mg/2mL S.C. Q4W (N=65)” |
| Placebo | “Placebo (N=65)” |

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

EMERGE began on 2026-06-29 and has reported no efficacy or safety results; the company expects top-line results in the second half of 2028, and a company presentation lists updated EMERGE top-line guidance by the end of 2027. Enrollment is limited to approximately 195 adults aged 18 to 80 years who are acetylcholine receptor antibody positive, with an MG-ADL score of 6 or more and a QMG score of 10 or more, so participants with anti-MuSK, anti-LRP4, or seronegative generalized myasthenia gravis are not represented. The randomized, placebo-controlled period lasts 17 weeks, and longer-term data will come from an optional 104-week extended treatment period that includes an open-label extension.

Source: [ClinicalTrials.gov NCT07647510](https://clinicaltrials.gov/study/NCT07647510); [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm); [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
